Search research articles
Contact Us
Filters
Showing results (121-130 of 132) with videos related to
Page
of 14
Sort By:
Hepatology International
|
March 27, 2023
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
Te-Sheng Chang, Chung-Feng Huang, Hsing-Tao Kuo, et al.
The Kaohsiung Journal of Medical Sciences
|
January 20, 2025
Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan
Szu-Jen Wang, Chung-Feng Huang, Te-Sheng Chang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
August 21, 2024
Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry
Tyng-Yuan Jang, Chung-Feng Huang, Te-Sheng Chang, et al.
Infectious Diseases and Therapy
|
April 28, 2024
Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan
Chun-Chi Yang, Chung-Feng Huang, Te-Sheng Chang, et al.
Hepatology International
|
January 21, 2024
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan
Ming-Lung Yu, Chi-Ming Tai, Lein-Ray Mo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
March 3, 2021
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
Chi-Yi Chen, Chung-Feng Huang, Pin-Nan Cheng, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
February 6, 2022
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan
Ching-Chu Lo, Chung-Feng Huang, Pin-Nan Cheng, et al.
Clinical and Molecular Hepatology
|
January 9, 2024
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program
Ming-Ying Lu, Chung-Feng Huang, Chao-Hung Hung, et al.
Infectious Diseases and Therapy
|
December 30, 2021
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
Pin-Nan Cheng, Lein-Ray Mo, Chun-Ting Chen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
August 1, 2021
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
Chung-Feng Huang, Kuo-Chih Tseng, Pin-Nan Cheng, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 132) with videos related to
Sort By:
Page
of 14
Hepatology International
|
March 27, 2023
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
Te-Sheng Chang, Chung-Feng Huang, Hsing-Tao Kuo, et al.
The Kaohsiung Journal of Medical Sciences
|
January 20, 2025
Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan
Szu-Jen Wang, Chung-Feng Huang, Te-Sheng Chang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
August 21, 2024
Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry
Tyng-Yuan Jang, Chung-Feng Huang, Te-Sheng Chang, et al.
Infectious Diseases and Therapy
|
April 28, 2024
Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan
Chun-Chi Yang, Chung-Feng Huang, Te-Sheng Chang, et al.
Hepatology International
|
January 21, 2024
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan
Ming-Lung Yu, Chi-Ming Tai, Lein-Ray Mo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
March 3, 2021
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
Chi-Yi Chen, Chung-Feng Huang, Pin-Nan Cheng, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
February 6, 2022
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan
Ching-Chu Lo, Chung-Feng Huang, Pin-Nan Cheng, et al.
Clinical and Molecular Hepatology
|
January 9, 2024
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program
Ming-Ying Lu, Chung-Feng Huang, Chao-Hung Hung, et al.
Infectious Diseases and Therapy
|
December 30, 2021
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
Pin-Nan Cheng, Lein-Ray Mo, Chun-Ting Chen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
August 1, 2021
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
Chung-Feng Huang, Kuo-Chih Tseng, Pin-Nan Cheng, et al.
Page
of 14